Month: May 2026

Not since the invention of the rubber outsole has the humble running shoe
undergone such a radical transformation. In the span of just a few years, footwear
engineers have rewritten the rulebook on what is biomechanically possible, lifting
world records off the track and delivering elite-level performance to everyday
runners worldwide. As we move through 2025 and into 2026, the pace of
innovation shows no sign of slowing. From laboratory-born foams that defy
conventional material science to geometry so aggressive it has regulators
scrambling, running shoes have become as much a feat of engineering as of
craftsmanship.

The Super-Foam Revolution
At the heart of every modern performance shoe is its midsole foam, and the
single biggest leap in recent years has been the shift away from traditional EVA
(ethylene-vinyl acetate) compounds toward two next-generation materials: PEBA
(polyether block amide) and ATPU (advanced thermoplastic polyurethane). EVA,
the workhorse of the industry for decades, compresses and loses energy with
every stride. PEBA and ATPU change the equation entirely.
PEBA-based foams — marketed under names such as Nike ZoomX, Adidas
Lightstrike Pro, and Saucony PWRRUN PB — are exceptionally light and springy,
returning a remarkable percentage of impact energy back to the runner with each
footfall. Think of them less like cushioning and more like a trampoline underfoot.
ATPU, the newer challenger, offers equally aggressive energy return with superior
durability. The ASICS Megablast and Puma Fast-R Nitro Elite 3 both deploy
ATPU to stunning effect in 2025, and the compound is rapidly scaling across
brand lineups heading into 2026. What was once reserved for $300 race-day
weapons is now trickling into everyday trainers — a genuine democratisation of elite performance.

Supercritical Foaming and the Science of Lightness

Alongside the chemistry of the foam itself, manufacturers have refined the
manufacturing process with a technique called supercritical foaming — injecting
nitrogen or carbon dioxide gas into molten polymer under extreme pressure
before allowing it to expand in a mould. The result is a cellular structure that is
simultaneously lighter, more resilient, and longer-lasting than conventionally
moulded foam. New Balance’s forthcoming 1080v15, due in early 2026, debuts an
entirely new compound called Infinion produced via this process, pushing the
heel stack to a near-maximum 40 mm while keeping the overall shoe weight
surprisingly low. Brooks has also adopted nitrogen-infused DNA Loft v3 foam in
its Adrenaline GTS 25, proving that even stability shoes aimed at overpronators
need not sacrifice liveliness for support.

Carbon Fibre Plates and the Propulsion Geometry
The carbon-fibre plate, first popularised by Nike’s Vaporfly series in 2017, has
become almost ubiquitous in high-end race footwear. Embedded in the midsole, a
curved carbon plate acts as a stiff lever that stores energy during the loading phase
and releases it explosively at toe-off, effectively adding mechanical propulsion to
a runner’s natural stride. Subsequent iterations have refined both the geometry
and composition of these plates: Adidas introduced its dual EnergyRods system,
arranging carbon rods in a biomechanically optimised arc, while Saucony and
ASICS have experimented with nylon-fibre composites to tune stiffness for
different distances. Nike’s Alphafly 4, arriving in early 2026, pairs its carbon plate
with a reworked Air unit for an even more propulsive toe-off, promising to
reclaim its standing as the marathon shoe of choice.
Research consistently demonstrates that well-designed plated shoes can
improve running economy — the energy cost of sustaining a given pace — by
roughly 2 to 4 percent compared with conventional trainers. Over a full
marathon, that efficiency gain translates directly into minutes off finishing times,
a margin large enough to be the difference between a personal best and a podium
position.

The Rise of Super Trainers
Perhaps the most significant cultural shift in running footwear is the blurring
of the line between daily trainer and race day rocket. Until recently, runners
maintained a strict two-shoe rotation: a heavy, durable workhorse for everyday
miles and a fragile, expensive carbon-plated racer reserved for competition.

Brands are now dismantling that divide with a new category: the super trainer.
These shoes strip out the rigid carbon plate — and its associated harshness — while
retaining the premium foam compound. The Adidas Adizero Evo SL exemplifies
the formula, placing Lightstrike Pro foam in a daily-wear chassis with a 39 mm
heel stack and a gentle 6 mm drop. The shoe delivers the trampoline-like energy
return of a race shoe without punishing the calves on a Tuesday morning
recovery run.

Stack Heights, Drop, and the Regulatory Debate
World Athletics limits competition shoes to a maximum 40 mm stack height
and one rigid plate — rules designed to preserve a degree of natural athletic
competition. Yet for the millions of recreational runners who will never toe an
elite start line, those regulations are irrelevant, and some brands have begun to
exploit that freedom with spectacular abandon. Puma’s aptly named Fast-RB
Nitro Elite pushes its heel stack to an extraordinary 58 mm, packing three carbon
plates into a structure designed to protect the legs of a marathon “tourist” rather
than win a championship. The shoe is technically banned from elite competition,
but for the amateur chasing a finish line rather than a podium, it represents the
outer edge of what cushioning technology can currently achieve.
Drop — the difference in stack height between heel and forefoot — has also
become a battleground. Traditional shoes sit at 8 to 10 mm, suiting heel strikers.
Under Armour’s Velociti Elite 3 challenges this orthodoxy with a radical 2 mm
drop, targeting biomechanically efficient midfoot strikers and signalling a broader
industry willingness to cater to a wider range of running gaits rather than
defaulting to a single standard geometry.

Upper Technology and Sustainability
Midsole innovation tends to steal the headlines, but upper construction has
evolved in parallel. Engineered knit uppers — using single-piece woven fabrics
that vary in density across zones of the foot — provide a sock-like fit that reduces
hotspots and slippage. Adidas’s woven Evo SL variant replaces the standard mesh
with an interlocked textile that offers improved breathability and a more
locked-in midfoot feel without added weight. Meanwhile, the industry is under
growing pressure to address its environmental footprint: brands including
Salomon and Brooks are incorporating recycled fibres and bio-based plastics into
uppers and outsoles, attempting to reconcile high performance with reducedenvironmental impact.

Looking Ahead
The trajectory of running shoe technology points toward an era in which elite
performance is no longer the exclusive preserve of professional athletes.
Supercritical foams, intelligently curved plates, and biomechanically tuned
geometry are converging into shoes that make every runner measurably faster,
more efficient, and better protected against fatigue. The challenge for brands and
regulators alike will be to manage a landscape in which the shoe itself is becoming
as significant a performance variable as training and talent. For the rest of us, the
golden age of running footwear is already here — and it fits in a shoebox.
Essay prepared May 2026. Sources: Sundried, Supwell, Runner’s World, and industry release data.

The Achilles tendon is the largest and strongest tendon in the human body,
connecting the gastrocnemius and soleus muscles of the calf to the calcaneus, or heel bone. Despite its remarkable tensile strength, it is also one of the most
commonly ruptured tendons in the body. Rupture typically occurs in physically
active individuals, particularly men between the ages of 30 and 50 who engage in recreational sports. The incidence of Achilles tendon rupture has risen
significantly over recent decades, mirroring increases in participation in sports
such as basketball, tennis, and distance running. The injury most often results
from sudden eccentric loading of the tendon, such as a forceful push-off or
unexpected dorsiflexion of the ankle. Effective treatment is essential to restore
function, prevent re-rupture, and enable patients to return to their pre-injury
activity level.

Diagnosis
Diagnosis of an Achilles tendon rupture is predominantly clinical. Patients
commonly describe a sudden, sharp pain in the back of the ankle, often likened
to being struck or kicked, even when no contact has occurred. Physical
examination typically reveals a palpable gap in the tendon, localised swelling,
bruising, and weakness in plantar flexion. The Thompson test, in which
squeezing the calf of a prone patient normally produces plantar flexion of the
foot, is a reliable diagnostic tool; absence of this response suggests a complete
rupture. Imaging is not always required for diagnosis but is frequently used to
confirm the extent of injury and guide management. Ultrasound is the first-line
imaging modality due to its accessibility, low cost, and dynamic capabilities.
Magnetic resonance imaging (MRI) provides greater anatomical detail and is
reserved for equivocal cases or pre-surgical planning.

Non-Operative Management
Historically, operative treatment was favoured due to concerns about higher
re-rupture rates with conservative management. However, contemporary
evidence has significantly challenged this view. Non-operative treatment
involves immobilisation of the ankle, typically in an equinus position (plantar
flexion), using a cast or functional brace, followed by a carefully structured
rehabilitation program. Early functional rehabilitation protocols, which allow
controlled weight-bearing and progressive range-of-motion exercises, have
demonstrated outcomes comparable to surgical repair in terms of re-rupture
rate and functional recovery. A landmark randomised controlled trial by Willits
et al. (2010) found no significant difference in re-rupture rates between operative
and non-operative groups when both received an accelerated rehabilitation
protocol. Non-operative management avoids surgical risks including wound
infection, nerve damage, and deep vein thrombosis, making it an increasingly
preferred option for lower-demand patients, the elderly, and those with
comorbidities that increase operative risk.

Operative Management
Surgical repair of the Achilles tendon involves suturing the torn ends of the
tendon together, restoring its continuity and tension. Open repair, the traditional
approach, provides direct visualisation of the tendon and is associated with low
re-rupture rates, typically cited at less than 3 to 5 percent. The procedure is
performed under general or regional anaesthesia, with the patient placed prone.
The torn tendon ends are identified, debrided, and repaired using strong
absorbable or non-absorbable sutures in a variety of configurations, the most
widely used being the Kessler and Krackow techniques. Percutaneous and
minimally invasive repair techniques have been developed to reduce the wound
complication rates associated with open surgery, which can be as high as 20
percent in some series. These techniques use small stab incisions and specialised
devices to pass sutures through the tendon with minimal soft tissue disruption.
Studies have shown minimally invasive approaches achieve equivalent strength
and functional outcomes to open repair while reducing complications, though
they carry a higher risk of sural nerve injury if not performed with meticulous
technique.

Rehabilitation
Regardless of whether management is operative or non-operative,
rehabilitation is a critical determinant of outcome. Modern rehabilitation
protocols emphasise early controlled mobilisation rather than prolonged
immobilisation. Weight-bearing in a functional boot with heel raises typically
commences within one to two weeks of injury or surgery. Progressive
range-of-motion exercises, strengthening of the calf complex, proprioceptive
training, and gradual reintroduction of sport-specific activities follow a
structured timeline over several months. Full return to sport is generally not
expected before nine to twelve months, and some studies report that peak
strength recovery may take up to two years. Physical therapy plays a pivotal role throughout recovery, with eccentric calf strengthening and plyometric loading forming the cornerstone of sport-specific rehabilitation. Patient compliance with rehabilitation protocols is strongly associated with favourable outcomes.

Complications and Prognosis
Both treatment pathways carry risks. Surgical complications include wound
dehiscence, infection, sural nerve injury, deep vein thrombosis, and pulmonary
embolism. Non-operative management carries a historically higher re-rupture
rate, though this gap has narrowed considerably with functional rehabilitation
protocols, with pooled re-rupture rates now reported in the range of 2 to 5
percent for both approaches. Long-term prognosis following Achilles tendon
rupture is generally favourable, with the majority of patients returning to
pre-injury activity levels. However, residual deficits in plantarflexion strength,
endurance, and power are common, and some patients report persistent
symptoms for years after injury. Psychological factors, including fear of
re-injury and reduced confidence in the limb, can also impede full functional
recovery.

Conclusion
The management of Achilles tendon ruptures has evolved considerably over
the past two decades. The traditional assumption that surgery is always superior
has been replaced by a more nuanced, evidence-based approach that recognises
non-operative functional rehabilitation as a viable and often equivalent
alternative for many patients. Treatment decisions should be individualised,
taking into account patient age, activity level, occupational demands, comorbidities, and patient preference. Operative repair may still be preferred in
young, high-demand athletes seeking to minimise re-rupture risk and optimise
the speed of return to sport. Regardless of the chosen approach, a structured and
progressive rehabilitation program is indispensable to achieving the best possible
functional outcome. Ongoing research into augmentation techniques, biologics,
and optimised rehabilitation protocols continues to refine and improve the
management of this challenging injury.

The human foot is a marvel of biomechanical engineering, composed of
twenty-six bones, thirty-three joints, and more than a hundred muscles, tendons,
and ligaments working in concert to support the body’s weight and propel it
forward. Yet within this precisely orchestrated architecture, anatomical
variations are surprisingly common. One of the most frequently encountered is
the accessory navicular, an extra ossicle (small bone) located on the medial aspect
of the foot near the navicular bone. Estimated to occur in approximately ten to
fourteen percent of the general population, it is most often an incidental finding
– a harmless quirk of development. In a smaller subset of individuals, however, it
becomes a significant source of medial foot pain, altered gait, and functional
disability. Understanding the anatomy, classification, biomechanical
implications, and treatment options of the accessory navicular is essential for any
clinician working with foot and ankle conditions.

Anatomy and Embryology
The navicular is a tarsal bone situated on the medial column of the foot,
articulating with the talus proximally and the three cuneiform bones distally. It
serves as the keystone of the medial longitudinal arch and is the primary
attachment site for the tibialis posterior tendon, one of the most important
dynamic stabilisers of that arch. The accessory navicular arises from a secondary
ossification centre that fails to fuse with the main navicular during skeletal
development. In most people, this centre either never appears or fuses
seamlessly during adolescence. In those who retain it, the result is a distinct bony
prominence on the medial and plantar aspect of the navicular.
Three subtypes have been described in the literature, most commonly
attributed to Geist (1914) and later refined by others. Type I, also called an os
tibiale externum, is a small sesamoid bone embedded entirely within the tibialis
posterior tendon and is generally asymptomatic. Type II is the most clinically

relevant: a larger ossicle connected to the navicular by a fibrocartilaginous
synchondrosis. Because the tibialis posterior tendon inserts partly onto this
accessory bone, mechanical forces across the junction can produce microtrauma,
inflammation, and pain. Type III represents a fused or partially fused accessory
navicular, creating a prominent ‘cornuate’ navicular with an enlarged medial
tuberosity. Although structurally fused, this type can still produce symptoms due
to its bony prominence and its effect on tendon mechanics.

Clinical Presentation
Accessory navicular syndrome – the symptomatic form of the condition –
most commonly presents in adolescence, coinciding with a period of rapid
growth and increased physical activity. It is somewhat more prevalent in females
than males, and a bilateral presentation is found in up to fifty percent of cases.
The hallmark symptom is medial foot pain, typically localised to the bony
prominence on the inner border of the midfoot. The area is often tender to
direct palpation, and the prominence itself may be visibly or palpably enlarged,
causing irritation from footwear. Activity-related pain – particularly running,
jumping, or prolonged standing – is a consistent complaint.
A key associated finding is pes planus, or flatfoot deformity. Because the
accessory navicular disrupts the normal insertion mechanics of the tibialis
posterior tendon, the dynamic support of the medial longitudinal arch is
compromised. Patients may consequently develop or worsen a pre-existing
flatfoot, contributing to broader biomechanical consequences such as hindfoot
valgus, forefoot abduction, and altered lower limb alignment. These secondary
changes can themselves become sources of pain and dysfunction if left
unaddressed.

Diagnosis
Diagnosis is primarily clinical but is confirmed radiographically.
Weight-bearing plain radiographs of the foot, including anteroposterior, lateral,
and oblique views, will typically demonstrate the accessory ossicle. The oblique
view is particularly valuable for visualising the synchondrosis in Type II cases.
Where plain films are inconclusive or when the extent of soft tissue involvement
needs assessment, magnetic resonance imaging (MRI) is the modality of choice.

MRI can identify bone marrow oedema at the synchondrosis – a reliable
indicator of active inflammation and the likely source of pain. Technetium bone
scanning has also been used to demonstrate increased uptake at the accessory
navicular site, confirming its symptomatic status.
Conservative Management
The vast majority of patients with symptomatic accessory navicular respond
well to non-operative treatment, and conservative management should always be
the first line of care. Rest from aggravating activities, non-steroidal
anti-inflammatory medications, and ice application form the cornerstone of
initial management. Immobilisation in a below-knee cast or a removable walking
boot for four to six weeks is highly effective in acute or severe flares, allowing the
inflamed synchondrosis to settle.
Once the acute phase has resolved, custom orthotic devices are the most
important tool for long-term symptom control. A well-fitted medial arch
support offloads the navicular prominence, reduces stress at the synchondrosis,
and helps correct the biomechanical consequences of the associated flatfoot
deformity. Footwear modification – favouring supportive, wide-toed shoes that
avoid direct pressure over the prominence – is equally important. Physiotherapy
targeting tibialis posterior strengthening, calf flexibility, and intrinsic foot muscle
activation is valuable in rebuilding dynamic arch support. Corticosteroid
injection into the synchondrosis can provide medium-term relief in refractory
cases, though its use is generally reserved for adults given the potential effects on
developing tissue in younger patients.

Surgical Management
When conservative measures fail after a sustained trial of at least three to six
months, surgical intervention is considered. The most widely performed
procedure is the Kidner operation, first described in 1929, which involves
excision of the accessory navicular and re-routing of the tibialis posterior tendon
to a more plantar and distal position on the native navicular. This re-attachment
is intended to improve the tendon’s mechanical advantage in supporting the
medial arch. Long-term outcomes following the Kidner procedure are generally
favourable, with the majority of patients reporting significant pain relief and

return to normal activities.
More recently, some surgeons have advocated for simple excision of the
ossicle without tendon re-routing, particularly in Type I cases or where the
tendon insertion is largely intact on the native navicular. Arthroscopic or
minimally invasive techniques for accessory navicular excision have also been
described, offering the potential advantages of smaller incisions, reduced soft
tissue disruption, and faster recovery. In cases with significant associated flatfoot
deformity, additional procedures to reconstruct the medial arch – such as
calcaneal osteotomy or medial column stabilisation – may be undertaken
concurrently.

The accessory navicular is a common anatomical variant that, in a
meaningful minority of individuals, evolves into a painful and functionally
limiting condition. Its close relationship with the tibialis posterior tendon and the
medial longitudinal arch means that its consequences can extend well beyond
simple bony prominences. A thorough understanding of its subtypes, clinical
presentation, and pathomechanics enables accurate diagnosis and the selection
of appropriate management strategies. With a well-structured conservative
programme, most patients achieve satisfactory outcomes without the need for
surgery. For those who do require operative intervention, modern techniques
offer reliable and durable relief. The accessory navicular is a reminder that even
the smallest structural variations in the foot can have outsized functional
consequences – and that attentive, individualised care makes all the difference.

On the warm evening of 10 September 1960, a slender Ethiopian soldier
jogged to the start line of the Olympic marathon in Rome. He wore no
shoes. While the rest of the field arrived in purpose-built racing flats, Abebe
Bikila planted his bare feet on the cobblestones of the Appian Way and,
within two hours and fifteen minutes, rewrote the history of distance
running. It was not merely a sporting triumph; it was a declaration of
African capability broadcast to a world that had long underestimated the
continent.

Abebe Bikila was born on 7 August 1932 in the small village of Jato, in
the mountains of central Ethiopia. He grew up as a shepherd boy,
accustomed to moving across vast, rocky highland terrain, often with little
or nothing on his feet. At the age of twenty-four he joined the Imperial
Bodyguard of Emperor Haile Selassie, where he was noticed for his
prodigious physical fitness and exceptional lung capacity. His formal
running career began almost by accident. A friend invited him to watch a
training session run by the Finnish coach Onni Niskanen, who had been
sent to Ethiopia to develop the country’s athletics programme. Niskanen
recognised the young guard’s potential immediately and began coaching
him in earnest. Bikila trained at altitudes above 2,000 metres, a natural
physiological advantage that would prove decisive in competition.
When Ethiopia’s Olympic selection committee chose Bikila for Rome
in 1960, he was virtually unknown outside his own country. He had never
run an international marathon. The decision to race barefoot was partly
practical and partly symbolic. Adidas, the official supplier, had run out of
shoes that fitted him properly. Bikila had trained barefoot throughout his
preparation and felt more comfortable without shoes on the hard surface.
Niskanen agreed. In hindsight, the decision was inspired.

The Rome marathon was run at night under flickering torchlight, a
deliberate homage to the classical world, with the course winding along the
ancient Appian Way and finishing at the Arch of Constantine. The
atmosphere was theatrical and haunting. Bikila bided his time in the early
stages, settling into a compact, metronomic stride that consumed the road
with quiet efficiency. By the halfway point he had moved into contention.
By the 30-kilometre mark he was at the front. Moroccan runner Rhadi Ben
Abdesselam, the pre-race favourite, tried to match him but could not. Bikila
crossed the finish line in 2 hours, 15 minutes and 16 seconds, breaking the
world record by nearly eight minutes. He was so composed upon finishing
that he immediately began stretching and performing calisthenics, as if the
race had barely taxed him.

The symbolism of the victory was enormous and was not lost on the
watching world. Ethiopia was one of only two African nations never
colonised by a European power, the other being Liberia. It had successfully
repelled an Italian invasion in 1896 at the Battle of Adwa, only to suffer
Mussolini’s brutal occupation from 1936 to 1941. That Bikila won on Italian
soil, and won in Rome itself, carrying the Ethiopian flag with his bare feet,
was a profound act of postcolonial pride. Whether or not he consciously
framed it in those terms, millions of Africans and people of African descent
did. He was the first Black African to win an Olympic gold medal, and he
had done it in the most emphatic manner imaginable.

Four years later, at the 1964 Tokyo Olympics, Bikila proved that Rome
had been no fluke. This time he wore shoes. He had undergone an
appendectomy just forty days before the race, and his doctors had advised
him not to compete. He ignored them. He won again, setting another world
record with a time of 2 hours, 12 minutes and 11 seconds, becoming the first
person in history to win consecutive Olympic marathon gold medals. Once
more he finished the race in a condition that left his rivals bewildered. He
told reporters he could have run another ten kilometres. Whether or not
that was bravado, no one had the legs to test it.
His story, however, took a devastating turn. In March 1969, Bikila was
involved in a car accident near Addis Ababa that left him paralysed from the waist down. The nation was grief-stricken. Yet Bikila, with characteristic
resilience, refused to accept defeat. He took up competitive archery and
handpulled sledging, competing in the 1970 Stoke Mandeville Games for
Paralympic athletes. He died on 25 October 1973 from a brain
haemorrhage, complications arising from his injury. He was forty-one
years old. Ethiopia declared a national day of mourning. Emperor Haile
Selassie attended the state funeral in person.

The legacy of Abebe Bikila extends far beyond athletics. He opened a
door that Ethiopian and Kenyan runners would sprint through in the
following decades, establishing East Africa as the dominant force in
long-distance running. Names like Mamo Wolde, Miruts Yifter, Haile
Gebrselassie, Kenenisa Bekele, and Eliud Kipchoge all run in his shadow. He
also helped shift the global perception of African athletes from exotic
curiosities to serious competitors worthy of respect and study. In the years
since his death, sports scientists have revisited his barefoot running style
with fresh eyes, noting that his natural gait anticipated many of the
biomechanical insights that would only gain mainstream attention half a
century later.

Statues and portraits of Bikila stand in Addis Ababa. His image appears
on Ethiopian stamps and currency. A stadium bears his name. Yet perhaps
the most enduring monument to the man is the simple image that the
world cannot forget: a slight figure running in darkness on ancient stones,
barefoot and unhurried, moving through history as if it were merely
another training run through the highlands he called home.